Current treatment of hepatitis B

Dusheiko, G.; Antonakopoulos, N.
January 2008
Gut;Jan2008, Vol. 57 Issue 1, p105
Academic Journal
The article offers information on the current treatment of Hepatitis B. It states that Hepatitis B is usually determined by the identification of HBsAg in serum. Moreover, the detection of viral DNA is the most particular method of establishing Hepatitis B viraenemia, and that standardized quantitative assays are essential for observing virus loads during antiviral therapy.


Related Articles

  • Tenofovir dominates other EASL therapies.  // PharmacoEconomics & Outcomes News;5/29/2010, Issue 604, p1 

    The article discusses research study in first-line tenofovir disoproxil fumarate (TDF) monotherapy against chronic hepatitis B. It references the study "Cost-Effectiveness Analysis of the EASL 2009 Clinical Practice Guidelines for Management of Chronic Hepatitis B in France, Italy, Portugal,...

  • Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients. Engell, Christian A.; Pham, Vinh Philip; Holzman, Robert S.; Aberg, Judith A. // ISRN Gastroenterology;2011, Special section p1 

    Goal. To study the effect of combination antiviral therapy with tenofovir and emtricitabine or lamivudine with and without prior monotherapy with lamivudine. Study. We reviewed charts of 31 HIV-/HBV-coinfected patients. Twelve 3TC-naïve patients initially received tenofovir plus...

  • The Study of Efficacy of Lamivudine in Patients with Severe Acute Hepatitis B. Jian-Wu Yu; Li-Jie Sun; Yong-Hua Zhao; Peng Kang; Shu-Chen Li // Digestive Diseases & Sciences;Mar2010, Vol. 55 Issue 3, p775 

    Severe acute hepatitis B is a rapid deterioration of liver function, which carries a high mortality rate. The aim of this study is to evaluate the efficacy of lamivudine in patients with severe acute hepatitis B. In this study, 80 patients with severe acute hepatitis B were randomly divided into...

  • Treatment of Hepatitis B e Antigen--Positive Chronic Hepatitis with Telbivudine or Adefovir. Chan, Henry L. Y.; Heathcote, E. Jenny; Marcellin, Patrick; Ching-Lung Lai; Mong Cho; Moon, Young M.; You-Chen Chao; Myers, Robert P.; Minuk, Gerald Y.; Jeffers, Lennox; Sievert, William; Bzowej, Natalie; Harb, George; Kaiser, Ralf; Xin-Jian Qiao; Brown, Nathaniel A. // Annals of Internal Medicine;12/4/2007, Vol. 147 Issue 11, p745 

    Background: The efficacy of nucleoside and nucleotide analogues for hepatitis B has been linked to the magnitude and durability of hepatitis B virus (HBV) suppression. Objective: To compare the antiviral efficacy of telbivudine and adefovir dipivoxil, and the effects of switching from adefovir...

  • Telbivudine versus Adefovir for Chronic Hepatitis B Virus (HBV) Infection.  // Clinical Infectious Diseases;6/1/2008, Vol. 46 Issue 11, pv 

    The article reports on the therapeutic effect of telbivudine and adefovir in patients with chronic hepatitis B virus (HBV) infection in Asia. Study shows that the reduction in the plasma HBV DNA level was dominant for patients who were initially given telbivudine. It was found out that the rates...

  • Entecavir outlasts the alternatives for affordable hep B therapy.  // PharmacoEconomics & Outcomes News;8/9/2008, Issue 559, p1 

    The article discusses research on the cost-effectiveness of the longer-term treatment, short-term treatment and entecavir for patients with HBeAg-negative chronic hepatitis B. It references a study by D. L. Veenstra and colleagues published in the June 15, 2008 issue of "Alimentary Pharmacology...

  • HEPATITIS B: NEWS FROM THE RESEARCH WORLD. Piramanayagam, Paramasivan; Choudhuri, Gourdas // Hepatitis B Annual;2007, Vol. 4, p133 

    Hepatitis B is the leading cause of viral hepatitis in the developing world; about 400 million people are infected with chronic hepatitis B worldwide. Continuing research on hepatitis B over the last few decades has added considerably to our understanding of its replication, pathology, natural...

  • Nabi advances European commercialization strategy by filing for Nabi-HB approval.  // PharmaWatch: Biotechnology;August 2004, Vol. 3 Issue 8, p12 

    Nabi Biopharmaceuticals Inc. has filed its first marketing authorization application in Europe. The company is seeking approval to market its Nabi-HB Intravenous for the treatment of hepatitis B under the trade name Hebig. The company sees the move as an important first step toward establishing...

  • Interesting Chinese Articles on Hepatitis & Chinese Medicine. Flaws, Bob // Townsend Letter;Dec2007, Issue 293, p140 

    The article discusses the Chinese medical treatment of chronic hepatitis B (CHB). It is stated that Chinese medicine has faced many difficulties in finding a treatment for CHB because viruses are difficult to eliminate with Chinese medicinals. The nature of the condition is lingering and...


Read the Article


Sign out of this library

Other Topics